SAN DIEGO, March 3, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced it has appointed Dr. Peter K. Honig and Dr. Patrick Y. Yang to its Board of Directors. The company also announced that concurrent with these appointments, Dr. Johan Kördel will step down from his current role as director.
Help employers find you! Check out all the jobs and post your resume.